Last reviewed · How we verify
Standard Treatment for CHF post AMI
At a glance
| Generic name | Standard Treatment for CHF post AMI |
|---|---|
| Sponsor | CellProthera |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- EXCELLENT (EXpanded CELL ENdocardiac Transplantation) (PHASE2)
- Tezspire Cardiac Events PASS
- COLchicine to Prevent Sympathetic Denervation After an Acute Myocardial Infarction (PHASE2, PHASE3)
- Tailoring Post Discharge - Remote Education and Access for Cardiac Health (NA)
- Efficacy and Safety of Early Initiation of Vericiguat in Heart Failure After Acute Myocardial Infarction (PHASE4)
- The RECOVER IV Trial (NA)
- MSCs for Prevention of MI-induced HF (PHASE3)
- Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |